FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2075281231> ?p ?o ?g. }

• W2075281231 endingPage "214" @default.
• W2075281231 startingPage "202" @default.
• W2075281231 abstract "Evidence suggests that 30–50% of patients suffering from major depressive disorder (MDD) are classified as suffering from treatment resistant depression (TRD) as they have an inadequate response to standard antidepressants. A key feature of this patient population is the increased incidence of co-morbid symptoms like anxiety and pain. Recognizing that current standards of care are largely focused on monoaminergic mechanisms of action (MOAs), innovative approaches to drug discovery for TRD are targeting glutamate hyperfunction. Here we describe the in vitro and in vivo profile of GRN-529, a novel negative allosteric modulator (NAM) of metabotropic glutamate receptor 5 (mGluR5). In cell based pharmacology assays, GRN-529 is a high affinity (Ki 5.4 nM), potent (IC50 3.1 nM) and selective (>1000-fold selective vs mGluR1) mGluR5 NAM. Acute administration of GRN-529 (0.1–30 mg/kg p.o.) had dose-dependent efficacy across a therapeutically relevant battery of animal models, comprising depression (decreased immobility time in tail suspension and forced swim tests) and 2 of the co-morbid symptoms overrepresented in TRD, namely anxiety (attenuation of stress-induced hyperthermia, and increased punished crossings in the four plate test) and pain (reversal of hyperalgesia due to sciatic nerve ligation or inflammation). The potential side effect liability of GRN-529 was also assessed using preclinical models: GRN-529 had no effect on rat sexual behavior or motor co-ordination (rotarod), however it impaired cognition in mice (social odor recognition). Efficacy and side effects of GRN-529 were compared to standard of care agents (antidepressant, anxiolytic or analgesics) and the tool mGluR5 NAM, MTEP. To assess the relationship between target occupancy and efficacy, ex vivo receptor occupancy was measured in parallel with efficacy testing. This revealed a strong correlation between target engagement, exposure and efficacy across behavioral endpoints, which supports the potential translational value of PET imaging to dose selection in patients. Collectively this broad spectrum profile of efficacy of GRN-529 supports our hypothesis that negative allosteric modulation of mGluR5 could represent an innovative therapeutic approach to the treatment of TRD. This article is part of a Special Issue entitled ‘Metabotropic Glutamate Receptors’." @default.
• W2075281231 created "2016-06-24" @default.
• W2075281231 creator A5004362084 @default.
• W2075281231 creator A5013943246 @default.
• W2075281231 creator A5015700466 @default.
• W2075281231 creator A5024179300 @default.
• W2075281231 creator A5024722202 @default.
• W2075281231 creator A5025811678 @default.
• W2075281231 creator A5029252316 @default.
• W2075281231 creator A5029375747 @default.
• W2075281231 creator A5036363790 @default.
• W2075281231 creator A5045389168 @default.
• W2075281231 creator A5047046715 @default.
• W2075281231 creator A5051379328 @default.
• W2075281231 creator A5053695507 @default.
• W2075281231 creator A5062226284 @default.
• W2075281231 creator A5063642114 @default.
• W2075281231 creator A5064017219 @default.
• W2075281231 creator A5066492196 @default.
• W2075281231 creator A5067944628 @default.
• W2075281231 creator A5074640835 @default.
• W2075281231 creator A5082653632 @default.
• W2075281231 creator A5090701159 @default.
• W2075281231 creator A5091646209 @default.
• W2075281231 date "2013-03-01" @default.
• W2075281231 modified "2023-10-18" @default.
• W2075281231 title "Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression" @default.
• W2075281231 cites W1525839404 @default.
• W2075281231 cites W1967308562 @default.
• W2075281231 cites W1969561355 @default.
• W2075281231 cites W1973412317 @default.
• W2075281231 cites W1978157729 @default.
• W2075281231 cites W1980049394 @default.
• W2075281231 cites W1980188005 @default.
• W2075281231 cites W1990188497 @default.
• W2075281231 cites W1997113206 @default.
• W2075281231 cites W2002519594 @default.
• W2075281231 cites W2004331086 @default.
• W2075281231 cites W2007412962 @default.
• W2075281231 cites W2010641582 @default.
• W2075281231 cites W2016098542 @default.
• W2075281231 cites W2017050324 @default.
• W2075281231 cites W2019658937 @default.
• W2075281231 cites W2023081218 @default.
• W2075281231 cites W2023634568 @default.
• W2075281231 cites W2024636695 @default.
• W2075281231 cites W2025005051 @default.
• W2075281231 cites W2028682826 @default.
• W2075281231 cites W2028884770 @default.
• W2075281231 cites W2032142851 @default.
• W2075281231 cites W2032739515 @default.
• W2075281231 cites W2041320073 @default.
• W2075281231 cites W2043473753 @default.
• W2075281231 cites W2043713804 @default.
• W2075281231 cites W2047801483 @default.
• W2075281231 cites W2055333010 @default.
• W2075281231 cites W2055667475 @default.
• W2075281231 cites W2061070984 @default.
• W2075281231 cites W2061731402 @default.
• W2075281231 cites W2066564897 @default.
• W2075281231 cites W2073047063 @default.
• W2075281231 cites W2074631079 @default.
• W2075281231 cites W2076023426 @default.
• W2075281231 cites W2086305648 @default.
• W2075281231 cites W2094850136 @default.
• W2075281231 cites W2094920961 @default.
• W2075281231 cites W2104600881 @default.
• W2075281231 cites W2106042714 @default.
• W2075281231 cites W2109334244 @default.
• W2075281231 cites W2109699997 @default.
• W2075281231 cites W2110960534 @default.
• W2075281231 cites W2125608178 @default.
• W2075281231 cites W2129134595 @default.
• W2075281231 cites W2141841738 @default.
• W2075281231 cites W2146169076 @default.
• W2075281231 cites W2146659162 @default.
• W2075281231 cites W2147753672 @default.
• W2075281231 cites W2153677278 @default.
• W2075281231 cites W2319201633 @default.
• W2075281231 doi "https://doi.org/10.1016/j.neuropharm.2012.04.007" @default.
• W2075281231 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22551786" @default.
• W2075281231 hasPublicationYear "2013" @default.
• W2075281231 type Work @default.
• W2075281231 sameAs 2075281231 @default.
• W2075281231 citedByCount "67" @default.
• W2075281231 countsByYear W20752812312012 @default.
• W2075281231 countsByYear W20752812312013 @default.
• W2075281231 countsByYear W20752812312014 @default.
• W2075281231 countsByYear W20752812312015 @default.
• W2075281231 countsByYear W20752812312016 @default.
• W2075281231 countsByYear W20752812312017 @default.
• W2075281231 countsByYear W20752812312018 @default.
• W2075281231 countsByYear W20752812312019 @default.
• W2075281231 countsByYear W20752812312020 @default.
• W2075281231 countsByYear W20752812312021 @default.
• W2075281231 countsByYear W20752812312022 @default.
• W2075281231 countsByYear W20752812312023 @default.
• W2075281231 crossrefType "journal-article" @default.

• next